玻璃体内注射雷珠单抗与康柏西普治疗特发性脉络膜新生血管的临床疗效对比

目的　对比分析玻璃体内注射雷珠单抗与康柏西普治疗特发性脉络膜新生血管（idiopathic choroidal neovascularization，ICNV）的临床疗效。方法　选取2016年1月至2018年6月我院收治的ICNV患者90例（90眼），依据患者治疗情况分为雷珠单抗组及康柏西普组，每组患者各45例（45眼）。康柏西普组患者采取玻璃体内注射康柏西普0.05 mL进行治疗，雷珠单抗组采取玻璃体内注射雷珠单抗0.05 mL进行治疗。对两组患者治疗前及治疗3个月、6个月后最佳矫正视力、黄斑中心凹厚度以及治疗结束后不良反应发生率进行对比分析。结果　康柏西普组治疗前及治疗3个月、6个月后最佳矫正视力、黄斑中心凹厚度分别为0.34±0.10、0.60±0.25、0.80±0.20和（374.10±1.18）μm、（289.02±1.30）μm、（215.06±1.20）μm；雷珠单抗组分别为0.33±0.11、0.57±0.24、0.78±0.23和（373.55±1.15）μm、（288.97±1.23）μm、（215.11±1.17）μm。治疗前两组患者最佳矫正视力、黄斑中心凹厚度比较，差异均无统计学意义（均为P＞0.05）；治疗3个月、6个月后最佳矫正视力均高于治疗前，黄斑中心凹厚度均低于治疗前，差异均有统计学意义（均为P＜0.05）。治疗不同时间后，康柏西普组患者最佳矫正视力、黄斑中心凹厚度与雷珠单抗组相差均不大（均为P＞0.05）。治疗结束后康柏西普组不良反应发生率为11.11%，雷珠单抗组为8.89%，两组不良反应发生率差异无统计学意义（χ²=0.274，P＞0.05）。结论　玻璃体内注射雷珠单抗与康柏西普治疗ICNV后，患者最佳矫正视力均提高，黄斑中心凹厚度变薄，且不良反应发生率降低。

Comparative study on clinical efficacy between intravitreal injection of Ranibizumab and Conbercept in treatment of idiopathic choroidal neovascularization

Objective To compare the clinical efficacy between intravitreal injection of Ranibizumab and Conbercept in the treatment of idiopathic choroidal neovascularization(ICNV).Methods Totally 90 patients(90 eyes)with ICNV who received intravitreal injection of Ranibizumab or Conbercept in our hospital from January 2016 to June 2018,were randomly divided into Ranibizumab group and Conbercept group,45 patients(45 eyes)in each group.Patients in Conbercept group received intravitreal injection of 0.05 mL Conbercept,and those in Ranibizumab group received intravitreal injection of 0.05 mL Ranibizumab.Best corrected visual acuity(BCVA)and central foveal thickness before treatment,3 months and 6 months after treatment,and incidence of adverse reactions after treatment were compared between the two groups.Results Before treatment,3 months and 6 months after treatment,BCVA were 0.34±0.10,0.60±0.25 and 0.80±0.20,and central foveal thickness were(374.10±1.18)μm,(289.02±1.30)μm and(215.06±1.20)μm for patients in Conbercept group;BCVA were 0.33±0.11,0.57±0.24 and 0.78±0.23,and central foveal thickness were(373.55±1.15)μm,(288.97±1.23)μm and(215.11±1.17)μm for patients in Ranibizumab group.There were no statistical differences in BCVA or central foveal thickness between two groups before treatment(all P>0.05).At 3 months and 6 months after treatment,BCVA were higher than those before treatment,and central foveal thickness were lower than those before treatment(all P<0.05).At different time points after treatment,the BCVA and central foveal thickness in Conbercept group were not significantly different from those in Ranibizumab group(all P>0.05).After treatment,the incidence of adverse reactions was 11.11%in Conbercept group,and 8.89%in Ranibizumab group.No significant difference was found between the two groups(χ^2=0.274,P>0.05).Conclusion After intravitreal injection of Ranibizumab and Conbercept for patients with ICNV,BCVA gets improvement,central foveal thickness becomes thinner,and the incidence of adverse reactions decreases.